Stockreport

Opiant Pharmaceuticals Announces Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose

Opiant Pharmaceuticals, Inc.  (OPNT) 
Last opiant pharmaceuticals, inc. earnings: 3/4 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.opiant.com/investor-overview
PDF Based on FDA Feedback, Opiant Intends to Pursue 505 (b)(2) Development Pathway  Opiant Anticipates Submitting an NDA for this Product Candidate in 2020 SANTA MONICA, C [Read more]